Skip to Content

Seres Therapeutics Inc MCRB

Morningstar Rating
$0.78 +0.03 (3.75%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MCRB is trading at a 31% discount.
Price
$0.79
Fair Value
$6.56
Uncertainty
Extreme
1-Star Price
$9.52
5-Star Price
$4.28
Economic Moat
Svmqb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MCRB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.75
Day Range
$0.750.80
52-Week Range
$0.736.87
Bid/Ask
$0.76 / $0.78
Market Cap
$117.82 Mil
Volume/Avg
3,021 / 4.9 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.79
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
233

Comparables

Valuation

Metric
MCRB
AVIR
MORF
Price/Earnings (Normalized)
Price/Book Value
0.602.45
Price/Sales
0.792,798.21
Price/Cash Flow
Price/Earnings
MCRB
AVIR
MORF

Financial Strength

Metric
MCRB
AVIR
MORF
Quick Ratio
1.3817.8628.43
Current Ratio
1.7818.2428.94
Interest Coverage
−8.19
Quick Ratio
MCRB
AVIR
MORF

Profitability

Metric
MCRB
AVIR
MORF
Return on Assets (Normalized)
−22.71%−15.46%−19.79%
Return on Equity (Normalized)
−16.16%−20.47%
Return on Invested Capital (Normalized)
−41.39%−19.92%−23.98%
Return on Assets
MCRB
AVIR
MORF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTswtbvxdcPknpr$571.0 Bil
VRTX
Vertex Pharmaceuticals IncCxkfjgmYsrxs$107.8 Bil
REGN
Regeneron Pharmaceuticals IncLsfvkplKkldb$106.1 Bil
MRNA
Moderna IncYnwbddjsbRrnfq$42.3 Bil
ARGX
argenx SE ADRHfdfqjvcHrjp$23.7 Bil
BNTX
BioNTech SE ADRPqtpdxwTfyg$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncTbsrdnxtkZldpcm$19.4 Bil
BMRN
Biomarin Pharmaceutical IncFjyvsxdlNsxqqd$16.7 Bil
RPRX
Royalty Pharma PLC Class AFcphrlcnrCzsdsj$13.6 Bil
INCY
Incyte CorpWphfzlhXbvzhyn$12.8 Bil

Sponsor Center